On August 12, Sirio Pharma (300791.SZ) released its 2024 semi-annual report, revealing a total operating revenue of $273.63 million USD, an increase of $61.26 million USD compared to the same period last year, marking two consecutive years of growth. This represents a year-on-year increase of 28.85%. The net profit attributable to shareholders was $21.15 million USD, an increase of $7.32 million USD compared to the same period last year, reflecting a year-on-year rise of 52.66%. Source: Sirio Pharma Semi-Annual Report
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE